Top Tweets for #ColoRectal

Rhythm Biosciences Limited $RHY is transitioning from research and development into an active commercial medical diagnostics company focused on affordable, blood-based tests for early-stage cancer screening. Its lead diagnostic platform, ColoSTAT, boasts a high 90.3% sensitivity for all-stage colorectal cancer and avoids the unpleasant collection processes of traditional stool-based tests. Commercial scaling is underway through a major logistics partnership with 4Cyte Pathology, providing sample collection infrastructure across more than 1,000 phlebotomy sites in Australia. Although the firm remains unprofitable in its initial launch phase, its long-term valuation prospects are supported by a $24.8 billion USD global colorectal screening market and plans to secure public reimbursement. Will this diagnostic platform successfully drive widespread clinician adoption and secure the government funding needed to achieve its high-case growth targets?